Status:
COMPLETED
Pueraria Lobata and Pueraria Thomsonii for Mild Dyslipidemia
Lead Sponsor:
Jiangxi University of Traditional Chinese Medicine
Conditions:
Dyslipidemias
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease. Maintaining normal levels of lipid indicators can significantly reduce the risk of atherosclerotic cardiovascular d...
Detailed Description
Pueraria is an important Chinese herbal medicine. The Pharmacopoeia of the People's Republic of China classifies the Pueraria as Pueraria lobata and Pueraria thomsonii according to the different sourc...
Eligibility Criteria
Inclusion
- Marginally elevated low-density lipoprotein (LDL-C), 3.4 to 4.1 mmol/L
- Informed consent to the study and signed the informed consent form
Exclusion
- Patients who have a history of allergy to Pueraria Lobata or Pueraria Thomsonii.
- Patients who have taken lipid-lowering drugs within a week
- Patients with secondary dyslipidemia caused by other diseases or medications taken.
- Pregnant or lactating women.
- Patients who combine cognitive dysfunction, disorders of consciousness, psychiatric disorders, dyslexia or verbal communication dysfunction
- Patients with a combination of other serious diseases, such as malignant tumors, hepatic or renal insufficiency, cardiovascular or cerebrovascular disease, etc.
Key Trial Info
Start Date :
June 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 22 2022
Estimated Enrollment :
174 Patients enrolled
Trial Details
Trial ID
NCT04861376
Start Date
June 5 2021
End Date
January 22 2022
Last Update
July 3 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanchang Hongdu Hospital of Traditional Chinese Medicine
Nanchang, Jiangxi, China, 330004
2
The Affiliated Hospital of Jiangxi University of Chinese Medicine
Nanchang, Jiangxi, China, 330004